What it sells
The smart testing platform that unlocks digital health at home.
Business model breakdown
Economics: what it saves and how it charges
Claims molecular accuracy at lower cost than any other CLIA-waived system; hardware/test model implied, no figures.
Distribution: how it reaches customers
Waitlist and partnership/BD inquiries; not yet commercial (pending FDA review).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.